Roche Acquires Zealand Pharma Obesity Drug

This is a news story, published by CNBC, that relates primarily to Pharma news.

Pharma news

For more Pharma news, you can click here:

more Pharma news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Swiss pharmaceutical giant Roche

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Zealand Pharma news, Zealand Pharma CEO news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Danish biotech Zealand Pharma

CNBC

•

Health

Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate

Summary

Nutrition label

74% Informative

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma 's obesity drug candidate.

Shares of Zealand Pharma jumped as much as 29% shortly after the announcement, while Roche added 4.6% .

Deal will see the two companies co-develop and co-commercialize petrelintide as a standalone therapy.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive